EUVIMEDEUVIMED entdecken
Crossref

Ring‐Contracted Artemisinin Derivatives as Novel CDK 4/6 Inhibitors: Synthesis and Anti‐Breast Cancer Evaluation

Jun-Jie Zhu, Yi Ai, Jun-Hui Wu, Chang-Guang Zeng, Zhen Cui, Zheng-Ping Zhang, Jia-Yi Zhu, Chang-Qi Wang, Hang Zhong iD

Chemistry & Biodiversity · 2024

DOI: 10.1002/cbdv.202400086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2024. Verfasst von Jun-Jie Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Guizhou University, 550025, Guiyang, China. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 6, Artemisinins, Cyclin-Dependent Kinase 4, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Guizhou University Cultivation Project, Guizhou Provincial Science and Technology Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The endoperoxide group of artemisinins is universally accepted an essential group for their anti‐cancer effects. In this study, a series of D‐ring‐contracted artemisinin derivatives were constructed by combining ring‐contracted artemisinin core with fragments of functional heterocyclic molecules or classical CDK4/6 inhibitors to identify more efficacious breast cancer treatment agents. Twenty‐six novel hybridized molecules were synthesized and characterized by HRMS, IR, 1 H‐NMR and 13 C NMR. In antiproliferative activities and kinase inhibitory effects assays, we found that the antiproliferative effects of B01 were close to those of the positive control Palbociclib, with GI 50 values of 4.87±0.23 μM and 9.97±1.44 μM towards T47D cells and MDA‐MB‐436 cells respectively. In addition, the results showed that B01 was the most potent compound against CDK6/cyclin D3 kinase, with an IC 50 value of 0.135±0.041 μM, and its activity was approximately 1/3 of the positive control Palbociclib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase 6ArtemisininsCyclin-Dependent Kinase 4Antineoplastic AgentsProtein Kinase InhibitorsCell ProliferationBreast NeoplasmsDrug Screening Assays, AntitumorHumansStructure-Activity RelationshipCell Line, TumorMolecular StructureFemaleDose-Response Relationship, DrugMolecular Docking Simulation

Stichwörter der Autor:innen

CDK4/6 inhibitorsCDK6/cyclin D3 kinaseD-ring-contracted artemisinin derivativesantiproliferative activities

Substanzen

Cyclin-Dependent Kinase 6ArtemisininsCyclin-Dependent Kinase 4Antineoplastic AgentsProtein Kinase InhibitorsCDK6 protein, humanCDK4 protein, humanartemisinin

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Guizhou University, 550025, Guiyang, China.
  • Guizhou Engineering Laboratory for Synthetic Drugs, 550025, Guiyang, China.
  • Technical Department of Criminal Investigation Branch, Deyang Police Office, 618000, Deyang, China.

ORCID-Profile: Hang Zhong

Förderung

  • Guizhou University Cultivation Project
  • Guizhou Provincial Science and Technology Foundation

Zitieren

APA

Zhu, J. J., Ai, Y., Wu, J. H., Zeng, C. G., Cui, Z., Zhang, Z. P., Zhu, J. Y., Wang, C. Q., & Zhong, H. (2024). Ring‐Contracted Artemisinin Derivatives as Novel CDK 4/6 Inhibitors: Synthesis and Anti‐Breast Cancer Evaluation. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202400086

Vancouver

Zhu JJ, Ai Y, Wu JH, Zeng CG, Cui Z, Zhang ZP, et al. Ring‐Contracted Artemisinin Derivatives as Novel CDK 4/6 Inhibitors: Synthesis and Anti‐Breast Cancer Evaluation. Chemistry & Biodiversity. 2024. doi:10.1002/cbdv.202400086

BibTeX
@article{Zhu2024,
  author = {Zhu, Jun-Jie and Ai, Yi and Wu, Jun-Hui and Zeng, Chang-Guang and Cui, Zhen and Zhang, Zheng-Ping and Zhu, Jia-Yi and Wang, Chang-Qi and Zhong, Hang},
  title = {Ring‐Contracted Artemisinin Derivatives as Novel CDK 4/6 Inhibitors: Synthesis and Anti‐Breast Cancer Evaluation},
  journal = {Chemistry & Biodiversity},
  year = {2024},
  doi = {10.1002/cbdv.202400086}
}
Kostenlos starten →